NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, RM 200 ABC

June 26, 2013

http://www.state.nj.us/humanservices/dmahs/boards/durb/

AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for April 17, 2013 meeting (pages 3-9; Tab 1)

IV. Secretary’s report (page 11; Tab 2)

V. Old Business
   A. Proposed educational newsletter for Type2 diabetes treatment options (pages 13-16; Tab 3)
   B. Mental Health Update…Dr. Linda Gochfeld

VI. New Business
   A. Protocols review (Tab 4) (abbreviations (page 17)
      1. Modafinil (Provigil®) (pages 19-21)
      2. Atypical antipsychotics (pages 22-24)
      3. Omega-3-Acid ethyl esters (page 25)
      4. NSAIDs (Cox-2 Inhibitor) (pages 26-28)

VII. Informational Highlights/Reports
    1. Molina Prior Authorization Report (pages 29-30; Tab 5)
    2. Summary of DURB Action Items (page 31; Tab 5)
    3. ACA non-billing provider by specialty (page 32; Tab 5)
    4. NJ HMO Reports 1st Quarter 2013 (pages 33-36 Tab 6)
    5. DHS and DHSS Programs Top Drugs Report (pages 37-50; Tab 7)
    6. PACT information (page 51; Tab 8)
    7. Medication information (pages 53-57; Tab 9)
       (a) FDA approves labels with lower doses for zolpidem sleep drugs
       (b) FDA approves Breo® for COPD lung disease
       (c) Researchers Debate Risks Of GLP-1-Based Therapies
       (d) FDA Approves Nimodipine Oral Solution For Subarachnoid Hemorrhage